ATAP-M8

ATAP-M8 (also known as ATAP-iRGD-M8) is a peptide therapeutic developed by TRIM-edicine for the treatment of various cancers, including prostate cancer and late-stage solid tumors. It is an optimized version of an amphipathic tail-anchoring peptide (ATAP) derived from the human anti-apoptotic protein Bfl-1 (BCL2A1). The drug functions through a pro-apoptotic mechanism by targeting mitochondrial membrane permeability to induce cancer cell death. To enhance tumor selectivity and cellular penetration, the ATAP sequence is conjugated with an internalizing RGD (iRGD) peptide, which facilitates selective tumor targeting and internalization. ATAP-M8 has received class 1 innovative drug candidate designation from China's Center for Drug Evaluation (CDE) and entered Phase 1 clinical trials in March 2022. Preclinical data indicated that intravenous administration of the peptide effectively suppressed tumor growth in prostate cancer models with minimal systemic toxicity.

Other names

ATAP-iRGD-M8ATAP-iRGD-M-8ATAP-iRGD-M 8